Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MALTOMA
MCID: LYM129
MIFTS: 67

Lymphoma, Mucosa-Associated Lymphoid Type (MALTOMA)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

MalaCards integrated aliases for Lymphoma, Mucosa-Associated Lymphoid Type:

Name: Lymphoma, Mucosa-Associated Lymphoid Type 57 75 38
Malt Lymphoma 57 38 12 59 75 55 15
Mucosa-Associated Lymphoid Tissue Lymphoma 12 59 73
Gastric Lymphoma, Primary 57 75 55
Lymphoma, Malt, Somatic 57 75 13
Extranodal Marginal Zone B-Cell Lymphoma 59 73
Marginal Zone B-Cell Lymphoma 75 73
Maltoma 59 75
Mucosa-Associated Lymphatic Tissue Lymphoma 59
Familial Primary Gastric Lymphoma 73
Lymphoma, B-Cell, Marginal Zone 44
Primary Gastric Lymphoma 75
Gastric Lymphoma 73

Characteristics:

Orphanet epidemiological data:

59
malt lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (United States),1-9/100000 (Europe); Age of onset: Adult; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Gastrointestinal diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare haematological diseases


Sources

Summaries for Lymphoma, Mucosa-Associated Lymphoid Type

About this section
UniProtKB/Swiss-Prot : 75 Lymphoma, mucosa-associated lymphoid type: A subtype of non-Hodgkin lymphoma, originating in mucosa-associated lymphoid tissue. MALT lymphomas occur most commonly in the gastro- intestinal tract but have been described in a variety of extranodal sites including the ocular adnexa, salivary gland, thyroid, lung, thymus, and breast. Histologically, they are characterized by an infiltrate of small to medium-sized lymphocytes with abundant cytoplasm and irregularly shaped nuclei. Scattered transformed blasts (large cells) also are present. Non-malignant reactive follicles are observed frequently. A pivotal feature is the presence of lymphoepithelial lesions, with invasion and partial destruction of mucosal glands and crypts by aggregates of tumor cells.

MalaCards based summary : Lymphoma, Mucosa-Associated Lymphoid Type, also known as malt lymphoma, is related to nodal marginal zone b-cell lymphoma and follicular lymphoma. An important gene associated with Lymphoma, Mucosa-Associated Lymphoid Type is BCL10 (BCL10, Immune Signaling Adaptor), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Amoxicillin and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include b cells, thyroid and salivary gland, and related phenotypes are hyperhidrosis and nausea and vomiting

Disease Ontology : 12 A marginal zone B-cell lymphoma that has material basis in mucosal tissue involved in antibody production.

OMIM : 57 The concept of mucosa-associated lymphoid tissue (MALT) lymphomas was introduced by Isaacson and Wright (1983). MALT lymphomas are now recognized as a distinct subtype of non-Hodgkin lymphoma (605027). B-cell lymphomas of mucosa-associated lymphoid tissue (MALT lymphomas) are the most common form of lymphoma arising in extranodal sites, in most cases arising in the gastric mucosa (Isaacson and Spencer, 1995). (137245)

Sources

Related Diseases for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Diseases related to Lymphoma, Mucosa-Associated Lymphoid Type via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)
# Related Disease Score Top Affiliating Genes
1 nodal marginal zone b-cell lymphoma 34.5 MALT1 BCL6
2 follicular lymphoma 32.6 MME IGH CCND1 BCL6 BCL10
3 lymphoma 32.1 MALT1 CXCR5 CCND1 BCL6 BCL10
4 tracheal lymphoma 31.0 MME CD5
5 diffuse large b-cell lymphoma 30.9 MME MALT1 FOXP1 CD5 CARD11 BCL6
6 b-cell lymphomas 30.8 MME MALT1 FOXP1 CD5 CD40 CCND1
7 marginal zone b-cell lymphoma 30.7 MME MALT1 FOXP1 CD5 CCND1 BIRC3
8 composite lymphoma 30.6 BCL6 CD5
9 lymphoma, hodgkin, classic 30.5 MME CD5 BCL6
10 follicular lymphoma 1 30.4 BCL6 BCL10 IGH
11 central nervous system lymphoma 30.4 MALT1 FOXP1 BCL6
12 mantle cell lymphoma 30.3 MME MALT1 IGH CD5 CD40 CCND1
13 primary cutaneous marginal zone b-cell lymphoma 30.2 MALT1 BCL10
14 prostate lymphoma 30.1 MALT1 CD5 BIRC3
15 chromosomal triplication 30.1 BCL6 MALT1
16 breast lymphoma 30.1 BCL6 CD5
17 splenic marginal zone lymphoma 30.0 MALT1 CD5 BIRC3 BCL6
18 bladder lymphoma 30.0 MME CD5
19 leukemia, chronic lymphocytic 30.0 IGH CXCR5 CXCR3 CD5 CD40 CCND1
20 peripheral t-cell lymphoma 29.8 MME CXCR3 CXCL13 CD5 BCL6
21 lymphoma, non-hodgkin, familial 29.4 MME MALT1 IGH CXCR5 CD5 CD40
22 nodal marginal zone lymphoma 11.5
23 adenocarcinoma 10.5
24 helicobacter pylori infection 10.4
25 gastritis 10.4
26 sjogren syndrome 10.3
27 gastric adenocarcinoma 10.3
28 gastric cancer 10.3
29 orofaciodigital syndrome viii 10.3 MALT1 BIRC3 BCL10
30 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.3 CXCR5 BCL6
31 adenoma 10.3
32 heart lymphoma 10.2 MME BCL6
33 autoimmune disease 10.2
34 thyroiditis 10.2
35 gastrointestinal lymphoma 10.2 BIRC3 MME
36 testicular lymphoma 10.2 BCL6 FOXP1 MME
37 t-cell/histiocyte rich large b cell lymphoma 10.2 BCL6 IGH MME
38 primary mediastinal large b-cell lymphoma 10.2 BCL6 FOXP1
39 intravascular large b-cell lymphoma 10.2 BCL6 CD5 MME
40 central nervous system hematologic cancer 10.2 MME CARD11 BCL6
41 langerhans cell histiocytosis 10.2
42 hepatitis b 10.2
43 hairy cell leukemia 10.2
44 dacryoadenitis 10.2
45 igg4-related ophthalmic disease 10.2
46 cll/sll 10.2 MME CD5 CCND1
47 lymphatic system cancer 10.2 MME CD5 BCL6
48 lung lymphoma 10.2 MALT1 CD5 BIRC3 BCL6
49 mature b-cell neoplasm 10.2 MME CD40 BCL6
50 lymphoblastic lymphoma 10.2 MME CD5 BCL6

Graphical network of the top 20 diseases related to Lymphoma, Mucosa-Associated Lymphoid Type:



Diseases related to Lymphoma, Mucosa-Associated Lymphoid Type
Sources

Symptoms & Phenotypes for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Clinical features from OMIM:

137245

Human phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type:

59 32 (show all 19)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000975
2 nausea and vomiting 59 32 hallmark (90%) Very frequent (99-80%) HP:0002017
3 constipation 59 32 frequent (33%) Frequent (79-30%) HP:0002019
4 recurrent respiratory infections 59 32 occasional (7.5%) Occasional (29-5%) HP:0002205
5 visual impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0000505
6 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
7 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
8 anemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001903
9 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
10 weight loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0001824
11 mediastinal lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0100721
12 abnormality of the thyroid gland 59 32 occasional (7.5%) Occasional (29-5%) HP:0000820
13 pulmonary infiltrates 59 32 hallmark (90%) Very frequent (99-80%) HP:0002113
14 b-cell lymphoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0012191
15 posterior uveitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012123
16 lymphadenopathy 59 Occasional (29-5%)
17 abnormality of the nasolacrimal system 59 Occasional (29-5%)
18 abnormal nasolacrimal system morphology 32 occasional (7.5%) HP:0000614
19 gastric lymphoma 32 HP:0045038

GenomeRNAi Phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 BCL10 BIRC2 BIRC3 CARD11 DUSP5 MALT1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 BCL10 BIRC2 BIRC3 CARD11 CCND1 CD40

MGI Mouse Phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 BCL10 BCL6 BIRC2 BIRC3 CCND1 CXCL13
2 hematopoietic system MP:0005397 10 BCL10 BCL6 BIRC2 BIRC3 CARD11 CCND1
3 immune system MP:0005387 9.83 BCL10 BCL6 BIRC2 BIRC3 CARD11 CCND1
4 normal MP:0002873 9.23 BCL6 BIRC2 BIRC3 CCND1 CD40 CD5
Sources

Drugs & Therapeutics for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Drugs for Lymphoma, Mucosa-Associated Lymphoid Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
2
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
3
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
4 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
5 Gastrointestinal Agents Phase 4,Phase 2,Not Applicable
6 Antiprotozoal Agents Phase 4,Phase 3,Phase 2
7 Antiparasitic Agents Phase 4,Phase 3,Phase 2
8 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
9 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Antacids Phase 4,Phase 2,Not Applicable
11 Anti-Ulcer Agents Phase 4,Phase 2,Not Applicable
12 Antimalarials Phase 4,Phase 2
13
Clarithromycin Approved Phase 3,Phase 2,Not Applicable 81103-11-9 84029
14
Metronidazole Approved Phase 3,Phase 2 443-48-1 4173
15
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
16
Chlorambucil Approved Phase 3,Phase 2 305-03-3 2708
17 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2,Not Applicable
18 Cytochrome P-450 CYP3A Inhibitors Phase 3,Phase 2,Not Applicable
19 Immunologic Factors Phase 3,Phase 2,Phase 1
20 Antirheumatic Agents Phase 3,Phase 2
21 Alkylating Agents Phase 3,Phase 2
22 Antineoplastic Agents, Alkylating Phase 3,Phase 2
23
Lenalidomide Approved Phase 2 191732-72-6 216326
24
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
26
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
27
Tetracycline Approved, Vet_approved Phase 2 60-54-8 5353990
28
Loperamide Approved Phase 2 53179-11-6 3955
29
Bismuth Subsalicylate Approved, Vet_approved Phase 2 14882-18-9 53629521
30
Omeprazole Approved, Investigational, Vet_approved Phase 2,Not Applicable 73590-58-6 4594
31
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
32
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
33
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
34
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
35
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
36
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
37
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
38
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
41
Everolimus Approved Phase 2 159351-69-6 6442177
42
Sofosbuvir Approved Phase 2 1190307-88-0 45375808
43
Ledipasvir Approved Phase 2 1256388-51-8 67505836
44
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
45
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
46 Cordycepin Investigational Phase 2 73-03-0
47 Angiogenesis Modulating Agents Phase 2
48 Immunosuppressive Agents Phase 2
49 Angiogenesis Inhibitors Phase 2
50 BB 1101 Phase 2

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection Recruiting NCT02553083 Phase 4 Nexium 40 mg;amoxicillin 1.5 gr;doxycycline 200 mg;Nexium 20 mg;clarythromicin 500 mg;amoxicillin 1gr
2 Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
3 Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma Active, not recruiting NCT00210353 Phase 3 chlorambucil (drug);rituximab+chlorambucil;rituximab
4 Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type Unknown status NCT00923663 Phase 2 Lenalidomide
5 Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas Unknown status NCT00783367 Phase 2 lenalidomide-low dose dexamethasone plus rituximab;Lenalidomide + Rituximab
6 Velcade in MALT Lymphoma Patients Completed NCT00373906 Phase 2 Bortezomib (Velcade)
7 Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach Completed NCT00002682 Phase 2 Amoxicillin;Bismuth Subsalicylate;Clarithromycin;Metronidazole Hydrochloride;Omeprazole;Tetracycline Hydrochloride
8 Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma Active, not recruiting NCT01808599 Phase 2 Chlorambucil;Rituximab i.v.;Rituximab s.c.
9 Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients Completed NCT00373646 Phase 2 Thalidomide, Pharmion
10 R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML) Active, not recruiting NCT01427114 Phase 2 rituximab, cyclophosphamide, vincristine, and prednisolone
11 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Completed NCT01015248 Phase 2 Rituximab and Bendamustine
12 VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy Completed NCT00210327 Phase 2 Bortezomib (drug)
13 VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy Terminated NCT00210392 Phase 2 Bortezomib (drug)
14 Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma Completed NCT00117156 Phase 2 Fludarabine;Rituximab
15 Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue Completed NCT01611259 Phase 2 Rituximab and Lenalidomide
16 A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae Completed NCT01010295 Phase 2 doxycycline (tetracycline)
17 Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) Completed NCT01164267 Phase 2 Everolimus
18 Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma Active, not recruiting NCT00377195 Phase 2
19 Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma Not yet recruiting NCT03261349 Phase 2 Ledipasvir and sofosbuvir
20 Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Completed NCT00656812 Phase 2 Rituximab;2-CdA
21 Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Completed NCT00989586 Phase 1, Phase 2
22 A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma Completed NCT00081809 Phase 2 autologous human tumor-derived HSPPC-96
23 Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies Recruiting NCT02924402 Phase 1
24 Reinfection After Eradication of Helicobacter Pylori Infection Unknown status NCT02674802
25 Endomicroscopy and Gastric MALT-lymphoma Completed NCT01583699 Not Applicable
26 Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori Completed NCT01264822 Rabeprazole Sodium
27 Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome Completed NCT00327132 Not Applicable Omeprazole, Amoxicillin, Clarithromycin
28 Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma Recruiting NCT02987127
29 Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma Not yet recruiting NCT03680586 Not Applicable
30 Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma Completed NCT00201422 Not Applicable
31 Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication" Completed NCT03219723 Vonoprazan;Amoxicillin hydrate;Clarithromycin;Metronidazole
32 Tumor Registry of Lymphatic Neoplasia Active, not recruiting NCT00889798
33 Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia Completed NCT02520895

Search NIH Clinical Center for Lymphoma, Mucosa-Associated Lymphoid Type

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Mucosa-Associated Lymphoid Type cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Lymphoma, Mucosa-Associated Lymphoid Type:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Lymphoma, Mucosa-Associated Lymphoid Type:
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: lymphoma, b-cell, marginal zone

Sources

Genetic Tests for Lymphoma, Mucosa-Associated Lymphoid Type

About this section
Sources

Anatomical Context for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

MalaCards organs/tissues related to Lymphoma, Mucosa-Associated Lymphoid Type:

41
B Cells, Thyroid, Salivary Gland, Breast, Lung, Thymus, Colon
Sources

Publications for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Articles related to Lymphoma, Mucosa-Associated Lymphoid Type:

(show top 50) (show all 869)
# Title Authors Year
1
Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy. ( 29582109 )
2018
2
Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary SjAPgren syndrome (pSS). ( 29424433 )
2018
3
MALT lymphoma: epidemiology, clinical diagnosis and treatment. ( 30364585 )
2018
4
Mucosal-associated Lymphoid Tissue (MALT) Lymphoma in Association With Pediatric Primary Sjogren Syndrome: 2 Cases and Review. ( 30371536 )
2018
5
Gastric MALT lymphoma and Helicobacter pylori. ( 30424932 )
2018
6
Sequential H. pylori eradication and radiation therapy with reduced dose compared to standard dose for gastric MALT lymphoma stages IE & II1E: a prospective randomized trial. ( 30327875 )
2018
7
Prognostic role of baseline 18 F-FDG PET/CT parameters in MALT lymphoma. ( 30299563 )
2018
8
Treatment Choice for Primary Rectal MALT lymphoma. ( 30215790 )
2018
9
Multiple keratotic papules and plaques on the trunk in Cowden's disease with MALT lymphoma. ( 28391632 )
2018
10
Clarithromycin as a "repurposing drug" against MALT lymphoma. ( 28771670 )
2018
11
Long-term course of precancerous lesions arising in patients with gastric MALT lymphoma. ( 29102522 )
2018
12
A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy. ( 29411260 )
2018
13
Mucosa-associated lymphoid-tissue (MALT) lymphoma of the rectum. ( 29474645 )
2018
14
Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma. ( 29563121 )
2018
15
Gastric MALT Lymphoma with Increased Plasma Cell Differentiation Showing Unique Endoscopic Features. ( 29666720 )
2018
16
Neuroendocrine Neoplasia in Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) of the Lung: A Case Report and Immunohistochemistry Analysis of Eight Pulmonary MALT Lymphomas. ( 29673288 )
2018
17
Evaluation of the diagnostic value of immunoglobulin clonal gene rearrangements in patients with parotid gland MALT lymphoma using BIOMED-2 protocol. ( 29699947 )
2018
18
MALT Lymphoma, Stress Ulcer and Cholinergic Nerves from the Viewpoint of Bilateral and Unilateral Truncal Vagotomy and Substance P. ( 29766790 )
2018
19
Rituximab monotherapy become an optimal treatment for primary pulmonary malt lymphoma. ( 29892543 )
2018
20
Rectal MALT lymphoma regression and anti-Helicobacter pylori therapy. ( 29961825 )
2018
21
Synchronous MALT lymphoma of the colon and stomach and regression after eradication of Strongyloides stercoralis and Helicobacter pylori. ( 29970607 )
2018
22
Gastric malt lymphoma mickmicking a submucosal tumor with complete response after chemotherapy. ( 30032924 )
2018
23
DWI-MRI vs CT in gastric MALT lymphoma-preliminary results in 19 patients. ( 30040435 )
2018
24
Colorectal MALT lymphoma: a rare clinical entity. ( 30103227 )
2018
25
Nodular pulmonary amyloidosis with primary pulmonary MALT lymphoma masquerading as metastatic lung disease. ( 28808514 )
2017
26
Orbital MALT Lymphoma after Autologous Stem Cell Transplantation for Follicular Lymphoma as Relapse of Diffuse Large B-Cell Lymphoma. ( 28331132 )
2017
27
Primary pulmonary MALT lymphoma presenting as non-resolving pneumonia. ( 28871587 )
2017
28
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). ( 28833354 )
2017
29
MALT lymphoma arising on a background of reactive pulmonary lymphoid hyperplasia in a patient with Systemic Lupus Erythematosus. ( 28945277 )
2017
30
A primary esophageal MALT lymphoma patient with<i>Helicobacter pylori</i>infection achieved complete remission after<i>H. pylori</i>eradication without anti-lymphoma treatment. ( 28053856 )
2017
31
A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. ( 28695630 )
2017
32
Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Colon: A Case Report and a Literature Review. ( 28469125 )
2017
33
Radiotherapy for mucosa-associated lymphoid tissue (MALT) lymphoma of the rectum: a case report. ( 28815477 )
2017
34
A MALT lymphoma prognostic index. ( 28720586 )
2017
35
MALT1 sequencing analyses in marginal zone B-cell lymphomas reveal mutations in the translocated MALT1 allele in an IGH-MALT1-positive MALT lymphoma. ( 28278699 )
2017
36
Treatment outcome and risk analysis for cataract after radiotherapy of localized ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma. ( 29037024 )
2017
37
A case of API2-MALT1-positive gastric MALT lymphoma with concomitant diffuse large B-cell lymphoma. ( 28626260 )
2017
38
Increased risk for metachronous gastric adenocarcinoma following gastric MALT lymphoma-A US population-based study. ( 28588876 )
2017
39
Successful Treatment of Catastrophic Antiphospholipid Antibody Syndrome Associated with MALT Lymphoma by Autologous Hematopoietic Stem Cell Transplantation. ( 28502938 )
2017
40
Primary MALT lymphoma of the duodenum. ( 27567330 )
2017
41
18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience. ( 27619357 )
2017
42
Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study. ( 27789481 )
2017
43
Bilateral MALT Lymphoma of the Breast. ( 28185346 )
2017
44
Significance of Cholinergic and Peptidergic Nerves in Stress-Induced Ulcer and MALT Lymphoma Formation. ( 28190393 )
2017
45
18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation. ( 28270020 )
2017
46
Clinical, histopathological, and molecular features of mucosa-associated lymphoid tissue (MALT) lymphoma carrying the t(X;14) (p11;q32)/GPR34-immunoglobulin heavy chain gene. ( 28278700 )
2017
47
Clinical aspects and therapy of gastrointestinal MALT lymphoma. ( 28288705 )
2017
48
MALT lymphoma: Genetic abnormalities, immunological stimulation and molecular mechanism. ( 28288707 )
2017
49
Primary Ocular Adnexal Extranodal Marginal Zone Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Presenting as Orbital Apex Syndrome. ( 28348632 )
2017
50
Daily CT guidance improves target coverage during definitive radiation therapy for gastric MALT lymphoma. ( 28377138 )
2017
Sources

Variations for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Cosmic variations for Lymphoma, Mucosa-Associated Lymphoid Type:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM36072 NOTCH2 haematopoietic and lymphoid tissue,extranodal,lymphoid neoplasm,MALT lymphoma c.4912C>T p.H1638Y 1:119922726-119922726 12
2 COSM35925 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1004T>G p.L335* 6:137878449-137878449 10
3 COSM303672 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.559C>T p.Q187* 6:137875760-137875760 10
4 COSM303675 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1507C>T p.Q503* 6:137878952-137878952 10
5 COSM303674 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1282G>T p.E428* 6:137878727-137878727 10
6 COSM303671 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.733A>T p.R245* 6:137876094-137876094 10
7 COSM303679 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.581T>C p.I194T 6:137875782-137875782 10
8 COSM303677 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1367G>T p.G456V 6:137878812-137878812 10
9 COSM303694 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1485T>A p.C495* 6:137878930-137878930 10
10 COSM85940 MYD88 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.794T>C p.L265P 3:38141150-38141150 10

Copy number variations for Lymphoma, Mucosa-Associated Lymphoid Type from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 119732 18 16100000 76117153 Gain MALT1 Mucosa-associated lymphoid tissue lymphomas
2 206010 6 135101251 139048099 Loss TNFAIP3 Mucosa-associated lymphoid tissue lymphomas
Sources

Expression for Lymphoma, Mucosa-Associated Lymphoid Type

About this section
Search GEO for disease gene expression data for Lymphoma, Mucosa-Associated Lymphoid Type.
Sources

Pathways for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Pathways related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.84 BCL10 BCL6 BIRC2 BIRC3 CARD11 CCND1
2
Cytokine Signaling in Immune system 66
Show member pathways
 13.21 BCL6 BIRC2 BIRC3 CCND1 CD40 DUSP5
3
NF-KappaB Family Pathway 64
Show member pathways
 12.53 BCL10 CARD11 CD40 MALT1 TRAF2
4
Immune response NFAT in immune response 22
Show member pathways
 12.45 BCL10 CARD11 CD40 IGH MALT1
5
Allograft rejection 1 37
Show member pathways
 12.35 BCL10 CARD11 CCND1 CD40 CXCL13 CXCR5
6
NF-kappaB Signaling 4
12.31 BCL10 BCL6 CARD11 CXCR5 MALT1 TRAF2
7
ICos-ICosL Pathway in T-Helper Cell 64
Show member pathways
 12.23 BCL10 CARD11 CD40 MALT1
8
B cell receptor signaling pathway (KEGG) 37
Show member pathways
 12.21 BCL10 BCL6 CARD11 MALT1
9
Apoptosis and Autophagy 4
12.03 BCL10 BIRC2 BIRC3 MALT1 TRAF2
10
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 65
Show member pathways
 11.83 CXCL13 CXCR3 CXCR5
11
TNF signaling pathway 37
11.8 BIRC2 BIRC3 TRAF2
12
TCR signaling in naive CD4+ T cells 1
Show member pathways
 11.79 BCL10 CARD11 MALT1
13
Small cell lung cancer 37
11.73 BIRC2 BIRC3 CCND1 TRAF2
14
LT-BetaR Pathway 64
Show member pathways
 11.66 BIRC2 CXCL13 TRAF2
15
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 22
Show member pathways
 11.57 BIRC2 BIRC3 CD40 TRAF2
16
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.5 BIRC2 BIRC3 CCND1
17
B Cell Development Pathways 65
11.28 BCL6 CD40 CD5 CXCR5 MME
18
NF-kappa B signaling pathway 37
11.15 BCL10 BIRC2 BIRC3 CARD11 CD40 MALT1
19
CD40/CD40L signaling 1
11.03 BIRC2 BIRC3 CD40 TRAF2
20
Canonical NF-kappaB pathway 1
11.01 BCL10 BIRC2 MALT1
Sources

GO Terms for Lymphoma, Mucosa-Associated Lymphoid Type

About this section

Cellular components related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.73 BCL10 BIRC2 BIRC3 HSPD1 MALT1 TRAF2
2 membrane raft GO:0045121 9.43 BCL10 BIRC2 BIRC3 CARD11 HSPD1 TRAF2
3 CD40 receptor complex GO:0035631 9.33 BIRC2 CD40 TRAF2
4 CBM complex GO:0032449 8.8 BCL10 CARD11 MALT1

Biological processes related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.97 BIRC2 BIRC3 CXCL13 CXCR3
2 inflammatory response GO:0006954 9.97 BCL6 CD40 CXCL13 CXCR3 S100A8
3 regulation of immune response GO:0050776 9.94 BCL6 CARD11 CD40 MADCAM1
4 T cell receptor signaling pathway GO:0050852 9.87 BCL10 CARD11 MALT1
5 Fc-epsilon receptor signaling pathway GO:0038095 9.87 BCL10 CARD11 MALT1
6 response to ethanol GO:0045471 9.86 BIRC2 CCND1 S100A8
7 chemotaxis GO:0006935 9.86 CXCL13 CXCR3 CXCR5 S100A8
8 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.85 HSPD1 S100A8 TRAF2
9 cell chemotaxis GO:0060326 9.84 CXCL13 CXCR3 CXCR5
10 chemokine-mediated signaling pathway GO:0070098 9.83 CXCL13 CXCR3 CXCR5
11 positive regulation of protein ubiquitination GO:0031398 9.81 BCL10 BIRC3 MALT1
12 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.8 BCL10 CARD11 MALT1
13 protein heterooligomerization GO:0051291 9.76 BCL10 BIRC2 BIRC3 TRAF2
14 tumor necrosis factor-mediated signaling pathway GO:0033209 9.73 BIRC2 BIRC3 CD40 TRAF2
15 positive regulation of B cell proliferation GO:0030890 9.72 BCL6 CARD11 CD40
16 regulation of inflammatory response GO:0050727 9.72 BCL6 BIRC2 BIRC3 FOXP1 S100A8
17 B cell activation GO:0042113 9.71 CD40 CXCR5 HSPD1 MALT1
18 NIK/NF-kappaB signaling GO:0038061 9.7 BIRC2 BIRC3
19 activation of NF-kappaB-inducing kinase activity GO:0007250 9.68 MALT1 TRAF2
20 positive regulation of interleukin-2 production GO:0032743 9.68 MALT1 TRAF2
21 regulation of innate immune response GO:0045088 9.68 BIRC2 BIRC3
22 B cell proliferation GO:0042100 9.67 CARD11 CD40 HSPD1
23 positive regulation of T cell activation GO:0050870 9.67 BCL10 CARD11 HSPD1 MALT1
24 negative regulation of necroptotic process GO:0060546 9.66 BIRC2 BIRC3
25 response to molecule of bacterial origin GO:0002237 9.66 BCL10 MALT1
26 negative regulation of B cell apoptotic process GO:0002903 9.65 BCL6 FOXP1
27 positive regulation of T cell cytokine production GO:0002726 9.65 MALT1 TRAF2
28 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.65 BIRC2 BIRC3 TRAF2
29 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.65 BCL10 BIRC2 BIRC3 CARD11 TRAF2
30 chronic inflammatory response GO:0002544 9.63 CXCL13 S100A8
31 germinal center formation GO:0002467 9.63 BCL6 CXCL13
32 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.63 BCL10 CARD11 CD40 MALT1 S100A8 TRAF2
33 inhibition of cysteine-type endopeptidase activity involved in apoptotic process GO:1990001 9.62 BIRC2 BIRC3
34 regulation of necroptotic process GO:0060544 9.61 BIRC2 BIRC3
35 response to fungus GO:0009620 9.61 BCL10 MALT1
36 regulation of T cell receptor signaling pathway GO:0050856 9.59 BCL10 MALT1
37 regulation of toll-like receptor signaling pathway GO:0034121 9.58 BIRC2 BIRC3
38 regulation of immunoglobulin secretion GO:0051023 9.57 CD40 TRAF2
39 regulation of cysteine-type endopeptidase activity GO:2000116 9.54 BIRC2 BIRC3
40 regulation of nucleotide-binding oligomerization domain containing signaling pathway GO:0070424 9.52 BIRC2 BIRC3
41 regulation of RIG-I signaling pathway GO:0039535 9.51 BIRC2 BIRC3
42 regulation of apoptotic process GO:0042981 9.5 BCL10 BCL6 BIRC2 BIRC3 CARD11 MALT1
43 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.17 BCL10 BIRC2 BIRC3 CARD11 CD40 MALT1
44 negative regulation of apoptotic process GO:0043066 10.08 BCL6 BIRC2 BIRC3 HSPD1 MALT1
45 apoptotic process GO:0006915 10.08 BCL10 BIRC2 BIRC3 CXCR3 S100A8 TRAF2

Molecular functions related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin-protein transferase activity GO:0004842 9.73 BIRC2 BIRC3 MALT1 TRAF2
2 ubiquitin protein ligase binding GO:0031625 9.62 BCL10 CD40 HSPD1 TRAF2
3 protease binding GO:0002020 9.58 BCL10 HSPD1 MALT1
4 CARD domain binding GO:0050700 9.37 BCL10 CARD11
5 C-X-C chemokine receptor activity GO:0016494 9.26 CXCR3 CXCR5
6 kinase activator activity GO:0019209 9.16 BCL10 MALT1
7 protein self-association GO:0043621 9.13 BCL10 FOXP1 MALT1
8 enzyme binding GO:0019899 9.02 BCL10 CCND1 CD40 HSPD1 TRAF2
9 protein binding GO:0005515 10.36 BCL10 BCL6 BIRC2 BIRC3 CARD11 CCND1
Sources

Sources for Lymphoma, Mucosa-Associated Lymphoid Type

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....